Fig. 3: KDM4B promotes anti-tumor response and immunotherapy through cGAS in vivo.
From: KDM4B enhances immune surveillance via demethylating cGAS
A and B Effects of KDM4B and cGAS double deficiency on B16F10 tumor growth (n = 6) analyzed by tumor picture (A), tumor volume (A), and tumor weight (B). C Effects of Kdm4b knockout on B16F10 tumor growth with anti-PD-1 antibody treatment (n = 6) displayed for tumor picture and tumor volume. D Kaplan–Meier analysis of overall survival in a set of 1416 melanoma samples. Statistical significance was determined by the log-rank test, p < 0.0001. High and low indicate the expression of KDM4B is up and down the median, respectively. E TCGA analysis for Kdm4b mRNA expression in SKCM, OV, THCA and CESE cells on the GEPIA website. Data are mean ± SEM for A–C, two-way ANOVA. *P < 0.05, **P < 0.01, ns, not significant.
